Objectives-To assess the impact of the background parenchymal echotexture on the accuracy of tumor size estimation using breast ultrasound (US).
T he most important clinical factor for the success of breast cancer surgery is complete removal of the cancer with adequate surgical margins.
1,2 A preoperative evaluation by imaging can help us detect additional occult malignant foci and accurately determine a patient's eligibility for breast conservation surgery. 3 Compared to conventional imaging, breast magnetic resonance imaging (MRI) can be used to measure tumor size more accurately. It can help us detect multifocal, multicentric, and contralateral breast cancer, which may change treatment planning. [4] [5] [6] Despite its high sensitivity, routine use of breast MRI in preoperative settings is controversial because it has been reported that MRI can increase the mastectomy rate without improving patients' outcomes. [7] [8] [9] Moreover, MRI-guided biopsy is not widely available, timeconsuming, expensive, and sometimes very challenging to perform depending on the visibility and location of the target. 10 For these reasons, whole-breast ultrasound (US) remains the mainstay for breast cancer staging in many institutions.
Normal breast parenchyma can show enhancement on dynamic contrast-enhanced MRI. This appearance is termed background parenchymal enhancement. Recent studies have shown that background parenchymal enhancement on breast MRI may either obscure or mimic malignancy, leading to false-negative or false-positive results. 3, [11] [12] [13] According to the American College of Radiology (Reston, VA) Breast Imaging Reporting and Data System lexicon, background parenchymal echotexture on breast US images can be classified into the following 3 categories: homogeneous-fat, homogeneousfibroglandular, and heterogeneous. Since background parenchymal enhancement can obscure or mimic breast cancer enhancement, a heterogeneous background echotexture might also affect the performance of breast US. However, studies focusing on the impact of the background parenchymal echotexture on the accuracy of preoperative tumor size measurement have not been reported yet.
Therefore, the objective of this study was to assess the impact of the background parenchymal echotexture on the accuracy of preoperative tumor size measurement. We also examined the relationship of accuracy with clinicopathologic and molecular profiles in patients with newly diagnosed breast cancer.
Materials and Methods

Study Population
The Institutional Review Board of Bundang CHA Medical Center approved this retrospective study. The requirement of informed consent was waived because of its retrospective nature. Between January 2014 and December 2015, a total of 206 consecutive patients with surgical and histologic diagnoses of invasive breast cancer underwent mammography, US imaging, and MRI at our institution. Of these 206 patients, those who had a history of breast radiation or mastectomy (n 5 15) or interstitial mammoplasty (n 5 2), those who had received hormonal therapy within the last 6 months before imaging studies (n 5 14), those who were lost to follow-up (n 5 16), and those who underwent neoadjuvant chemotherapy (n 5 19) were excluded from this study. Finally, a total of 140 patients were included in our study population.
Breast US Technique and Image Interpretation
At our institution, patients with breast cancer are usually evaluated with whole-breast US first to determine locoregional staging. Ultrasound examinations were performed with knowledge of clinical and mammographic findings with a 5-12-MHz transducer and an iU22 system (Philips Healthcare, Best, the Netherlands) or a 4-15-MHz transducer and an Aixplorer system (SuperSonic Imagine, Aix-en-Provence, France) by 1 of 4 board-certified radiologists with 4 to 15 years of experience in breast imaging.
The background parenchymal echotexture was classified as homogeneous or heterogeneous according to the Breast Imaging Reporting and Data System lexicon. The homogeneous background parenchymal echotexture was dived into 2 groups: homogeneous-fat and homogeneous-fibroglandular. However, there were only 2 patients with the homogeneous-fat type in this study group. Therefore, we used "homogeneous" to mean homogeneous-fibroglandular.
Two radiologists retrospectively reviewed US images in consensus for background parenchymal echotexture interpretation. A homogeneous echotexture was considered when there was a uniformly echogenic layer of glandular tissue. When tiny or linear hypoechoic areas were mixed in the gland, they were judged as homogeneous when the hypoechoic areas were scattered throughout the gland ( Figure 1A) . A heterogeneous echotexture was considered when the gland had multiple islands such as areas with increased or decreased echogenicity, including posterior acoustic shadowing ( Figure 1B) . The background parenchymal echotexture was evaluated in the contralateral normal breast to avoid subtle changes of echogenicity by breast cancer or ductal carcinoma in situ (DCIS).
Static US images acquired and stored in a picture archiving and communication system were reviewed, and the maximum diameter for tumor size measurement was recorded. When a lesion had a suspicious ductal extension, the maximum diameter included the ductal abnormality. For multifocal and multicentric breast cancers, only the index tumor was evaluated.
To correlate the background parenchymal echotexture with mammographic density and background parenchymal enhancement on MRI, 2 radiologists retrospectively reviewed and scored the mammographic density and background parenchymal enhancement in consensus. According to the Breast Imaging Reporting and Data System classification, mammographic density was scored as grade 1 (almost entirely fatty, < 25% glandular), grade 2 (scattered fibroglandular densities, 25%-50% glandular), grade 3 (heterogeneously dense, 50%-75% glandular), and grade 4 (extremely dense, > 75% glandular). Background parenchymal enhancement was scored as grade 1 (minimal, < 25% of glandular tissues showing enhancement), grade 2 (mild, 25%-50% of tissues showing enhancement), grade 3 (moderate, 50%-75% of tissues showing enhancement), and grade 4 (marked, > 75% of tissues showing enhancement). To standardize image interpretation, subtracted images of the second dynamic sequence (acquired 2 minutes after contrast agent injection) were used.
Histopathologic Analysis
Histopathologic results from US-guided core needle biopsy, US-guided needle localization, and surgery were considered the reference standards. Samples used for histopathologic examinations were prepared by making serial 5-mm slices for breast conservation surgical specimens and 5-to 10-mm slices for mastectomy specimens. Histologic diagnoses were made by 1 of 3 pathologists with 16 to 20 years of experience in breast histologic evaluation. The tumor diameter, histologic type, histologic or nuclear grade, and expression levels of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) were evaluated on the basis of surgical histopathologic findings. Estrogen receptor and PR positivity were defined by using a cutoff value of 10%; HER2 expression was considered negative when the immunohistochemical result was negative or had a staining score of 11; otherwise, it was considered positive when the staining score was 31. When fluorescence in situ hybridization was performed, the HER2 result according to fluorescence in situ hybridization was given a priority over that of the immunohistochemical result. The Ki-67 index was dichotomized into those with tumors expressing low and high Ki-67 levels using a 20% cutoff. The molecular type of the tumors was classified into 4 subtypes: luminal A (ER-positive and/or PR-positive, HER2-negative, and low Ki-67), luminal B (ER-positive and/or PR-positive, HER2-positive or HER2-negative, and high Ki-67), HER2-enriched (ER-negative, PR-negative, and HER2-positive), and triple-negative (ER-negative, PR-negative, and HER2-negative). We defined a tumor as invasive ductal cancer with a DCIS component when the DCIS extension was found on standard pathologic slides. As for invasive ductal cancers with DCIS, they were divided into 2 groups in accordance with the DCIS component quantity as follows: minimal DCIS (<25% of the neoplastic lesion) and extensive DCIS (25%).
Data Analysis
Clinical data such as age and menopausal status were collected by reviewing medical records. Continuous variables are shown as mean6 standard deviation, whereas categorical variables are presented as frequencies and percentages. If tumor size measurements compared to the pathologic size were within 65 mm, less than 5 mm, and greater than 5 mm, they were considered consistent, underestimated, and overestimated, respectively. The histopathologic result was used as the reference standard. v 2 and Fisher exact tests were used to compare the background parenchymal echotexture and clinicopathologic variables such as age, menopausal status, pathologic tumor subtype, hormone receptor status, and coexistence of DCIS. A multivariate logistic regression analysis was performed to identify the independent variables that were associated with the accuracy of tumor size measurements by breast US. All statistical analyses were performed with SPSS version 21.0 software (IBM Corporation, Armonk, NY). P < .05 was considered statistically significant.
Results
The mean age of the 140 patients included in the study was 53.3 years (range, 33-79 years). Sixty-three (45.0%) patients were premenopausal, and 77 (55.0%) were postmenopausal. Of the 140 patients, 77 (55.0%) a showed homogeneous background parenchymal echotexture, whereas 63 (45.0%) showed a heterogeneous echotexture. Seventy-nine (56.4%) patients underwent breast US with the 5-12-MHz transducer (Philips Healthcare) and 61 (43.6%) with the 4-15-MHz transducer (SuperSonic Imagine). The background parenchymal echotexture patterns were not influenced by the US machines (P 5 .224). The distribution of the background parenchymal echotexture according to patient age, menopausal status, mammographic density, and background parenchymal enhancement is summarized in Table 1 . A heterogeneous echotexture was significantly more frequent among women younger than 50 years than among women of 50 years or older (58.7% versus 41.3%; P < 0.001). It was more frequent among premenopausal women than postmenopausal women (74.6% versus 25.4%; P < .001). The background parenchymal echotexture was also significantly correlated with mammographic density and background parenchymal enhancement (both P < .001).
Based on the surgical histopathologic analysis, tumor types included 68 (49.0%) invasive ductal cancers without DCIS, 52 (37.0%) invasive ductal cancers with DCIS, 6 (4.0%) invasive lobular cancers, 6 (4.0%) mucinous cancers, 3 (2.0%) papillary cancers, and 5 (4.0%) other miscellaneous breast cancers. Pathologic characteristics of breast cancers according to background parenchymal echotexture patterns are shown in Table 2 . There was no significant correlation between the background parenchymal echotexture and tumor size, tumor grade, hormone receptor status, or molecular subtype of the tumor.
For primary index tumors, the sensitivity of breast US was 98.6% (138 of 140). Sensitivities of breast US for homogeneous and heterogeneous background parenchymal echotextures were 98.7% (76 of 77) and 98.4% (62 of 63), respectively. Two patients with missed breast The mean histologic size of the index tumor was 1.9 cm (range, 0.5-4.9 cm). The overall accuracy of tumor size on breast US was 76.4% (104 of 140). Thirteen (9.3%) patients were underestimated, whereas 20 (14.3%) were overestimated. The accuracy was significantly (P 5 Figures 2 and 3 ). In the homogeneous group, 7.8% (6 of 77) and 5.2% (4 of 77) of patients were underestimated and overestimated, respectively. In the heterogeneous group, 11.1% (7 of 63) and 25.4% (16 of 63) patients were underestimated and overestimated. Table 3 summarizes the clinicopathologic characteristics of invasive breast cancers and the accuracy of tumor size measurement. The accuracy was better for tumors in older (50 years) women than in younger (<50 years) women (P 5 .017) and also better for tumors in postmenopausal women than in premenopausal women (P 5 .008). Variables showing a significant association (P < .05) were entered as input variables for the multivariate analysis (Table 4 ). In the multivariate analysis, a heterogeneous background parenchymal echotexture (odds ratio [OR], 3.271; P 5 .009), a large tumor size (2 cm; OR, 2.431; P 5 .047), and the HER2-enriched subtype (OR, 3.511; P 5 .022) were independent factors associated with inaccurate tumor size measurement by breast US.
Discussion
Mammography is a primary imaging technique for breast examinations. However, the sensitivity of mammography is inversely related to breast density.
14 Similar to breast density on mammography, the degree of background parenchymal enhancement on breast MRI could lead to higher rates of false-positive or false-negative interpretations. 4, 15, 16 Although US plays a very important role in the clinical field as a screening and diagnostic imaging modality for breast disease, few studies have determined the effect of the background parenchymal echotexture on breast US performance. To the best of our knowledge, this work is the first study that determined the impact of the background parenchymal echotexture on preoperative tumor size estimation.
In accordance with previous studies, 17, 18 we found that the background parenchymal echotexture correlated significantly with age and menopausal status. This result supports the concept that the background parenchymal echotexture is influenced by breast hormonal changes. A heterogeneous echotexture was significantly more frequent in premenopausal women (<50 years). Izumori et al 19 found that stroma with densely packed connective tissue surrounding ducts was visualized as an isoechoic structure, whereas stroma with loosely packed fibrous connective tissues was hyperechoic. Differences in echogenicity between loose and dense stroma might cause heterogeneous background echogenicity. Due to changes in histologic characteristics with the menstrual cycle and changes in the background parenchymal echotexture, the diagnostic performance of preoperative breast US might be different depending on the patient's age and menopausal status.
For primary index tumors, breast US could detect 98.6% (138 of 140) of breast cancers in this study, consistent with results of previous studies. 3, 20 This detection rate was as high as that of breast MRI published previously. 21 Two cancers missed by breast US were microinvasive ductal cancers with extensive DCIS. Although there were segmentally distributed amorphous microcalcifications on mammography, we could not find any echogenic spots suggesting microcalcifications or other abnormal findings such as a mass, distortion, or dilated ducts. However, they were successfully visualized as suspicious non-masslike enhancement on breast MRI. This study revealed that the accuracy of breast US for tumor size measurement was 76.4% (100 of 140), with 9.3% (13 of 140) underestimates and 14.3% (20 of 140) overestimates. Several studies have reported the accuracy of tumor size measurement by breast US. Most of these studies were published in late 1990 and early 2000. The correlation rate between the US size and pathologic size was less than 70%. [22] [23] [24] However, other recent studies have shown higher concordant rates (65%-89%), 25 similar to the results of this study. These findings could be due to advances in US technology with good spatial and contrast resolution, thus leading to more accurate tumor size measurement. Therefore, results are better than those 10 years ago.
As expected, we found that the accuracy of tumor size measurement by breast US was influenced by the background parenchymal echotexture pattern. The accuracy of tumor size measurement by breast US for the homogeneous echotexture group (87.0%) was significantly (P 5 .001) higher than that for the heterogeneous group (63.5%). A heterogeneous background parenchymal echotexture might have affected the accuracy by increasing the rate of overestimation. In contrast, most previous studies found that breast US tends to underestimate breast tumor size. 22, 26, 27 Regarding possible reasons for tumor size underestimation by US, it has been suggested that the transducer size might be smaller than the tumor. 22 Another reason is that only the hypoechoic part of the lesion, not the hyperechoic halo surrounding the tumor, is often included in the measurement. 28 On the contrary, some studies have reported that breast US has a risk of overestimating tumor size, consistent with our results. Uematsu et al 20 reported that the most common finding of lesions that were overdiagnosed by US was ductal extension representing DCIS. They concluded that explicit guidelines for categorization of ductal extension on US images are necessary to decrease the false-positive rate for USdetected lesions. In fact, among 16 patients with a heterogeneous background parenchymal echotexture overestimated by US, 12 showed coexisting DCIS. In addition, we found that the accuracy was significantly lower for patients who had invasive ductal cancers with extensive DCIS than for those who had minimal DCIS in the heterogeneous echotexture group (P 5 .027). When we performed breast US examinations for patients with a heterogeneous background parenchymal echotexture, it was difficult to differentiate ductal extension of the tumor from multiple islandlike or tubular areas of decreased echogenicity in the normal breast. Measuring heterogeneous normal breast tissue as a part of ductal extension may lead to overestimation of the tumor size, which means that estimating ductal extension might be difficult for breast US to accurately measure tumor size.
It has been reported that invasive lobular cancer tends to spread diffusely or produce a minimal desmoplastic reaction, which can lead to underestimation of the tumor size on imaging. 29, 30 However, we did not find a significant difference in the accuracy of tumor size measurement by breast US for invasive lobular cancer. This finding could have been due to the small number of patients in this study. Although it was not an independent factor for accuracy in the multivariate analysis, we found that the accuracy of tumor size measurement for triple-negative breast cancer was higher than that for other tumor subtypes regardless of the background parenchymal echotexture pattern. It is well known that triple-negative breast cancer has distinctive US features, including a well-circumscribed margin and tumor necrosis with posterior acoustic enhancement. 31, 32 In addition, triple-negative breast cancer rarely shows suspicious microcalcifications and spiculations, with a low incidence of associated DCIS. [32] [33] [34] Consequently, we could measure the tumor size without underestimating or overestimating it, even for those with a heterogeneous background echotexture.
A recent study by Baek et al 35 revealed that HER2 negativity is highly associated with the accuracy of tumor size measurement by breast MRI. This result was very similar to ours. According to a meta-analysis of imaging features of tumors, HER2 overexpression is found to be associated with several imaging features, including the presence of microcalcifications, branching or fine linear calcifications, extremely dense breasts, a high suspicion of malignancy on mammography or US, irregularly shaped masses on US, and wash-out or fast initial kinetics on MRI. A circumscribed margin has a decreased probability of HER2 overexpression. 36 These radiologic characteristics of HER2-positive tumors make it difficult for radiologists to accurately assess the tumor size by breast US, especially for those with a heterogeneous background echotexture.
We also evaluated pathologic characteristics of breast cancers according to background parenchymal echotexture patterns. However, we found no significant association between the pathologic characteristics of breast cancer and the background parenchymal echotexture patterns. Previous studies on the association between breast density and background parenchymal enhancement and tumor characteristics have shown some inconsistencies. Although some studies suggested that breast density is associated with the hormone receptor status, one recent study reported that breast density had no association with pathologic characteristics in a multivariate analysis after adjusting for age and menopausal status. 37, 38 Therefore, a large comprehensive prospective study should be conducted in the future to This study had some limitations. First, it was a retrospective study from a single institution, which might have inevitably caused a selection bias. Second, the sample size was not sufficient to evaluate differences between histologic types. In our study population, most (86% [120 of 140]) of the cases were invasive ductal cancer. Only 6 (4%) patients had invasive lobular cancer. Third, the pathologic size was determined by pathologic reports. Slides were not reviewed by pathologists for this study. Although radiologists were unaware of the pathologic tumor size or extent, they were not blinded to other imaging methods when they performed breast US examinations or interpreted MRI. Therefore, one imaging method might have influenced others.
In conclusion, the background parenchymal echotexture affected the accuracy of tumor size measurement using breast US. When a patient has invasive breast cancer with a large size (2 cm) and an HER2-enriched type, the physician must be aware that the tumor size estimation by breast US could be inaccurate. On the basis of these results, the surgeon and patient could make an informed decision about proper management after preoperative breast US for tumor staging.
